Integrated API, formulation and CDMO manufacturer serving global pharma, biotech and animal-health customers.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 107 | 107 | 107 | 108 | 108 | 108 | 108 | 108 |
| Reserves | 1.7k | 2.6k | 3.3k | 3.9k | 4.1k | 4.5k | 4.7k | 5.1k |
| Borrowings | 1.1k | 1.4k | 1.7k | 1.7k | 2.1k | 2.4k | 2.2k | 2.1k |
| Other Liabilities | 872 | 1.5k | 1.6k | 1.2k | 1.4k | 1.6k | 2.4k | 2.2k |
| Total Liabilities | 3.7k | 5.6k | 6.6k | 7.0k | 7.7k | 8.6k | 9.4k | 9.5k |
| AssetsFixed Assets | 1.7k | 1.8k | 2.2k | 2.9k | 3.0k | 2.9k | 4.2k | 3.0k |
| CWIP | 67 | 324 | 755 | 357 | 156 | 336 | 541 | 569 |
| Investments | 58 | 319 | 362 | 384 | 635 | 740 | 261 | 891 |
| Other Assets | 1.9k | 3.2k | 3.3k | 3.3k | 3.8k | 4.6k | 4.4k | 5.0k |
| Total Assets | 3.7k | 5.6k | 6.6k | 7.0k | 7.7k | 8.6k | 9.4k | 9.5k |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
LAURUSLABS · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.